FR2852843B1 - Systeme galenique permettant le masquage du gout - Google Patents

Systeme galenique permettant le masquage du gout

Info

Publication number
FR2852843B1
FR2852843B1 FR0303568A FR0303568A FR2852843B1 FR 2852843 B1 FR2852843 B1 FR 2852843B1 FR 0303568 A FR0303568 A FR 0303568A FR 0303568 A FR0303568 A FR 0303568A FR 2852843 B1 FR2852843 B1 FR 2852843B1
Authority
FR
France
Prior art keywords
masking taste
galenic system
galenic
masking
taste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0303568A
Other languages
English (en)
French (fr)
Other versions
FR2852843A1 (fr
Inventor
Karim Ioualalen
Rosanne Raynal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0303568A priority Critical patent/FR2852843B1/fr
Application filed by Individual filed Critical Individual
Priority to CA2519962A priority patent/CA2519962C/fr
Priority to JP2006505750A priority patent/JP5072355B2/ja
Priority to PCT/FR2004/000729 priority patent/WO2004084856A2/fr
Priority to AU2004224601A priority patent/AU2004224601A1/en
Priority to NZ542590A priority patent/NZ542590A/en
Priority to MXPA05010217A priority patent/MXPA05010217A/es
Priority to KR1020057017992A priority patent/KR20060012576A/ko
Priority to EP04742337.1A priority patent/EP1605918B1/fr
Priority to US10/550,027 priority patent/US20070116728A1/en
Publication of FR2852843A1 publication Critical patent/FR2852843A1/fr
Application granted granted Critical
Publication of FR2852843B1 publication Critical patent/FR2852843B1/fr
Priority to US12/767,248 priority patent/US8911788B2/en
Priority to US14/523,999 priority patent/US9192679B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0303568A 2003-03-24 2003-03-24 Systeme galenique permettant le masquage du gout Expired - Lifetime FR2852843B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0303568A FR2852843B1 (fr) 2003-03-24 2003-03-24 Systeme galenique permettant le masquage du gout
EP04742337.1A EP1605918B1 (fr) 2003-03-24 2004-03-24 Systeme galenique pour le transport d'actif, procede de preparation et utilisation
PCT/FR2004/000729 WO2004084856A2 (fr) 2003-03-24 2004-03-24 Nouveau systeme galenique pour le transport d’actif, procede de preparation et utilisation
AU2004224601A AU2004224601A1 (en) 2003-03-24 2004-03-24 Novel galenical system for active transport, method for preparation and use
NZ542590A NZ542590A (en) 2003-03-24 2004-03-24 New galenic system for transport of an active constituent, preparation process and use
MXPA05010217A MXPA05010217A (es) 2003-03-24 2004-03-24 Nuevo sistmica galenico par transporte activo, metodo para preparacion y uso.
CA2519962A CA2519962C (fr) 2003-03-24 2004-03-24 Nouveau systeme galenique pour le transport d`actif, procede de preparation et utilisation
JP2006505750A JP5072355B2 (ja) 2003-03-24 2004-03-24 有効成分輸送のための新規なガレヌス製剤系、調製方法及び使用
US10/550,027 US20070116728A1 (en) 2003-03-24 2004-03-24 Novel galenical system for active transport, method for preparation and use
KR1020057017992A KR20060012576A (ko) 2003-03-24 2004-03-24 활성 성분의 전달을 위한 신규한 갈레누스 시스템, 제조방법 및 용도
US12/767,248 US8911788B2 (en) 2003-03-24 2010-04-26 Galenical system for active transport, method for preparation and use
US14/523,999 US9192679B2 (en) 2003-03-24 2014-10-27 Galenical system for active transport, method for preparation and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0303568A FR2852843B1 (fr) 2003-03-24 2003-03-24 Systeme galenique permettant le masquage du gout

Publications (2)

Publication Number Publication Date
FR2852843A1 FR2852843A1 (fr) 2004-10-01
FR2852843B1 true FR2852843B1 (fr) 2008-05-23

Family

ID=32947122

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0303568A Expired - Lifetime FR2852843B1 (fr) 2003-03-24 2003-03-24 Systeme galenique permettant le masquage du gout

Country Status (10)

Country Link
US (3) US20070116728A1 (enExample)
EP (1) EP1605918B1 (enExample)
JP (1) JP5072355B2 (enExample)
KR (1) KR20060012576A (enExample)
AU (1) AU2004224601A1 (enExample)
CA (1) CA2519962C (enExample)
FR (1) FR2852843B1 (enExample)
MX (1) MXPA05010217A (enExample)
NZ (1) NZ542590A (enExample)
WO (1) WO2004084856A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
FR2879930B1 (fr) * 2004-12-23 2007-08-31 Oralance Pharma Sa Nouveau systeme galenique pour le transport d'actif, procede de preparation et utilisation
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US8613956B2 (en) * 2008-06-23 2013-12-24 International Flora Technologies, Ltd. Cosmetic particles that transform from hard to soft particles comprising hydrogenated long-chain triglyceride oils
FR2935270A1 (fr) * 2008-08-28 2010-03-05 Oralance Pharma Composition pharmaceutique de temozolomide pour usage pediatrique
JP6305414B2 (ja) * 2012-10-18 2018-04-04 ディーエスエム アイピー アセッツ ビー．ブイ． カロテノイドを含むビードレット
US20160000714A1 (en) * 2013-03-06 2016-01-07 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
EP3766480A1 (en) 2014-06-10 2021-01-20 Capsugel Belgium NV Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
WO2016087261A1 (en) 2014-12-04 2016-06-09 Capsugel Belgium N.V. Lipid multiparticulate formulations
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
FR3059903B1 (fr) * 2016-12-08 2019-03-22 Salsarulo Pharma Medicament oral comprenant un laxatif osmotique incorpore dans une matrice a base de matieres grasses vegetales
UA122741C2 (uk) * 2016-12-08 2020-12-28 Сальсарюло Фарма Пероральний лікарський препарат, що включає осмотичне проносне, поміщене в матрицю на основі рослинних жирів
US10639607B2 (en) 2017-06-16 2020-05-05 Matralix Pte Ltd Systems and methods for preparing wax and lipid particles
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3755353A4 (en) 2018-02-23 2022-03-09 Finch Therapeutics Holdings LLC IMMUNOTHERAPIES RELATED TO MICROBIOME
FR3078630B1 (fr) * 2018-03-08 2021-05-14 Karim Ioualalen Mode de formulation sous forme de solide divise hydrophobe
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US20220257726A1 (en) 2019-07-18 2022-08-18 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
JP2022547330A (ja) 2019-09-13 2022-11-11 フィンチ セラピューティクス ホールディングス エルエルシー 自閉症スペクトラム障害を治療するための組成物および方法
KR20220101637A (ko) 2019-10-18 2022-07-19 핀치 테라퓨틱스 홀딩스 엘엘씨 박테리아 대사산물을 대상체에 전달하기 위한 조성물 및 방법
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
TW202140049A (zh) 2020-01-10 2021-11-01 美商芬奇治療控股有限責任公司 用於治療ｂ型肝炎（ｈｂｖ）及ｄ型肝炎（ｈｄｖ）之組合物及方法
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
US20240263251A1 (en) 2021-02-19 2024-08-08 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
CN113308045B (zh) * 2021-05-28 2022-03-22 宁波市鑫晟工贸实业有限公司 一种抗老化的塑料盒及其制备方法
IT202100014330A1 (it) * 2021-06-01 2022-12-01 The Ubeauty Com Llc Prodotto per la cura della pelle e procedimento per la sua realizzazione.
EP4475905A1 (en) * 2022-02-11 2024-12-18 Insitu Biologics, Inc. Sustained release cancer therapeutics formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146167A (en) * 1961-10-05 1964-08-25 Smith Kline French Lab Method of preparing sustained release pellets and products thereof
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
US4132375A (en) * 1976-01-21 1979-01-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Vortex-lift roll-control device
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
JPS63301815A (ja) * 1987-01-29 1988-12-08 Taisho Pharmaceut Co Ltd 経口製剤の製造方法
JP2700662B2 (ja) * 1988-06-22 1998-01-21 大正製薬株式会社 被覆製剤
JPH02200639A (ja) * 1989-01-31 1990-08-08 Shinfusou Seiyaku Kk 脂質被覆細菌製剤
IT1229856B (it) 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
EP0525307B1 (en) 1991-07-23 1996-03-06 American Cyanamid Company Stable compositions for parenteral administration and their use
DE4131562A1 (de) 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
CA2150119C (en) * 1992-11-30 2005-03-15 Robert C. Cuca Tastemasked pharmaceutical materials
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
DE4308282C2 (de) 1993-03-16 1994-12-22 Beiersdorf Ag Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices
AU7375598A (en) 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6692767B2 (en) 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
FR2769839B1 (fr) * 1997-10-21 1999-12-17 Odette Mercedes Salsarulo Composition anhydre a base de lactulose
FR2779962B1 (fr) * 1998-06-17 2002-12-06 Karim Ioualalen Composition cosmetique ou dermopharmaceutique sous forme de perles et procedes pour la preparation
AU4917900A (en) 1999-05-07 2000-11-21 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
DK1197207T3 (da) * 2000-10-10 2008-08-04 Wyeth Corp Stabile sammensætninger til parenteral indgivelse
JP3597823B2 (ja) 2002-02-07 2004-12-08 沢井製薬株式会社 固形製剤
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout

Also Published As

Publication number Publication date
KR20060012576A (ko) 2006-02-08
NZ542590A (en) 2009-02-28
US8911788B2 (en) 2014-12-16
JP5072355B2 (ja) 2012-11-14
WO2004084856A3 (fr) 2004-11-25
EP1605918A2 (fr) 2005-12-21
US9192679B2 (en) 2015-11-24
MXPA05010217A (es) 2006-03-28
CA2519962A1 (fr) 2004-10-07
US20150044297A1 (en) 2015-02-12
US20070116728A1 (en) 2007-05-24
FR2852843A1 (fr) 2004-10-01
JP2006521334A (ja) 2006-09-21
EP1605918B1 (fr) 2016-09-28
WO2004084856A2 (fr) 2004-10-07
AU2004224601A1 (en) 2004-10-07
US20100221298A1 (en) 2010-09-02
CA2519962C (fr) 2015-03-10

Similar Documents

Publication Publication Date Title
FR2852843B1 (fr) Systeme galenique permettant le masquage du gout
EP1682847A4 (en) ARROW SYSTEM
EP1659812A4 (en) RADIO COMMUNICATION SYSTEM
EP1619881A4 (en) PICTURE SETUP
EP1796021A4 (en) PRESENTATION SYSTEM
EP1800085A4 (en) DELIVERY SYSTEM
DE602004022101D1 (de) solches system
EP1940427A4 (en) encapsulation
DE602004030905D1 (de) Lautsprechergruppierungssystem
EP1687725A4 (en) SAFE PAYMENT SYSTEM
ITTO20030676A1 (it) Sistema di illuminamento per videoproiettore che utilizza
FR2858680B1 (fr) Systeme de plate-forme stabilisee
EP1736891A4 (en) PORTAL SYSTEM
EP1695173A4 (en) SYSTEM AND METHOD FOR FUNCTIONAL ELEMENTS
SE0301097L (sv) Lokaliseringssystem
FR2880072B1 (fr) Systeme de carburateur
EP1839219A4 (en) SYSTEM AND METHOD FOR CONFIGURING AN INTEGRATED CIRCUIT
NO20035626D0 (no) Metode
EP1799446A4 (en) SYSTEM FOR THINNERING A SEMICONDUCTOR WORKPIECE
FR2853438B1 (fr) Systeme automatise de reception-distribution
NO20035094D0 (no) Avbildingssystem
NO20035401D0 (no) Metode
NO20053578D0 (no) Undevanns-rorsystem
EP1620055A4 (en) HOLDER ARRANGEMENT
FR2864288B1 (fr) Systeme multimedia amphibie

Legal Events

Date Code Title Description
TP Transmission of property
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15